4.4 Review

Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis

Journal

CURRENT DRUG TARGETS
Volume 24, Issue 13, Pages 1023-1031

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0113894501254585230927100440

Keywords

Leishmania; visceral leishmaniasis; kala-azar; vaccines; neglected tropical disease (NTD); L. donovani

Ask authors/readers for more resources

Leishmaniasis is a vector-borne disease caused by a protozoan parasite, with no effective medicine/vaccine available. The development of new drugs is crucial, and a vaccine could be a low-risk and effective alternative. Although no vaccine has successfully passed clinical trials, the successful development of a vaccine for canine leishmaniasis provides hope.
Leishmaniasis is one of the Neglected Tropical Diseases (NTDs), a zoonotic disease of vector-borne nature that is caused by a protozoan parasite Leishmania. This parasite is transmitted by the vector sandfly into the human via a bite. Visceral leishmaniasis (VL), also called kala-azar, is the most fatal among the types of leishmaniasis, with high mortality mostly spread in the East Africa and South Asia regions. WHO report stated that approximately 3.3 million disabilities occur every year due to the disease along with approximately 50,000 annual deaths. The real matter of concern is that there is no particular effective medicine/vaccine available against leishmaniasis to date except a few approved drugs and chemotherapy for the infected patient. The current selection of small compounds was constrained, and their growing drug resistance had been a major worry. Additionally, the serious side effects on humans of the available therapy or drugs have made it essential to discover efficient and low-cost methods to speed up the development of new drugs against leishmaniasis. Ideally, the vaccine could be a low risk and effective alternative for both CL and VL and elicit long-lasting immunity against the disease. There are a number of vaccine candidates at various stages of clinical development and preclinical stage. However, none has successfully passed all clinical trials. But, the successful development and approval of commercially available vaccines for dogs against canine leishmaniasis (CanL) provides evidence that it can be possible for humans in distant future. In the present article, the approaches used for the development of vaccines for leishmaniasis are discussed and the progress being made is briefly reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available